Immunotherapy for Breast Cancer

Introduction

This article explains how immunotherapy is used in the treatment of breast cancer, including how it works, which types are available, who may be eligible, and what limitations exist. It is written for people researching breast cancer treatment options and aims to support informed conversations with healthcare professionals through clear, neutral information.

What Is Immunotherapy for Breast Cancer?

Immunotherapy is a type of cancer treatment that helps the body’s immune system recognise and attack cancer cells. In breast cancer, this approach has developed more slowly than in some other cancers, because many breast tumors do not naturally trigger a strong immune response. However, research has identified certain breast cancer subtypes that are more responsive to immune-based treatments.

Breast cancer cells can protect themselves by using proteins that signal immune cells to stand down. Immunotherapy works by blocking these signals, allowing immune cells—especially T cells—to identify cancer cells as abnormal and attack them. This approach differs from chemotherapy, which directly kills rapidly dividing cells, and hormone therapy, which blocks growth signals. Instead, immunotherapy modifies how the immune system behaves.

At present, immunotherapy is most commonly used in triple-negative breast cancer (TNBC), a subtype that does not respond to hormone therapy or HER2-targeted drugs. It is used in advanced disease and, in some cases, earlier stages alongside chemotherapy. Ongoing research is exploring whether immunotherapy can be expanded to other breast cancer subtypes.

Common Types of Immunotherapy Used

Fewer immunotherapy treatments are approved for breast cancer compared to lung cancer or melanoma, but several immune-based approaches are now part of standard care for selected patients.

Immune checkpoint inhibitors

These drugs block immune “brakes” that prevent the immune system from attacking cancer cells.

Examples include:

• PD-1 inhibitors, such as pembrolizumab

• PD-L1 inhibitors, used in specific clinical settings

Checkpoint inhibitors are mainly used for triple-negative breast cancer, particularly when the tumor expresses the PD-L1 protein.

Monoclonal antibodies

Some breast cancer treatments use antibodies that attach to cancer cells and mark them for destruction by the immune system. Trastuzumab (used in HER2-positive breast cancer) is a well-known example of a therapy with immune-mediated effects.

Antibody-drug conjugates (ADCs)

These therapies combine an antibody with a chemotherapy drug. The antibody guides the drug directly to the cancer cell, limiting exposure to healthy tissue. While often classified as targeted therapy, ADCs rely on immune system recognition to function effectively.

Cancer vaccines (experimental)

Vaccines designed to stimulate the immune system to recognise breast cancer-specific antigens are still in clinical trial stages and are not yet widely available.

Cellular therapies (research stage)

CAR T-cell and other adoptive cell therapies are being studied for breast cancer but are currently limited to research settings.

Who May Be Eligible?

Eligibility for immunotherapy in breast cancer depends on tumor biology, stage, and overall health. A specialist determines suitability using pathology and biomarker testing.

Common eligibility factors include:

• Breast cancer subtype: Immunotherapy is primarily used for triple-negative breast cancer.

• PD-L1 expression: Tumors may be tested to see if they express PD-L1, which can indicate a higher likelihood of response.

• Stage of cancer: It is used in metastatic breast cancer and, in some high-risk early-stage TNBC cases, before surgery.

• Response to previous treatments: Immunotherapy may be considered if standard therapies have been ineffective.

• General health and immune status: Autoimmune conditions or severe organ dysfunction may limit suitability.

Most hormone receptor–positive (ER+/PR+) breast cancers do not currently use checkpoint inhibitors outside of clinical trials.

Benefits and Limitations

Benefits

• Improved outcomes in TNBC: For a subtype historically difficult to treat, immunotherapy has improved survival and delayed progression in some patients.

• Durable responses: A subset of patients experience long-lasting benefit, even after treatment ends.

• Synergy with chemotherapy: Combining immunotherapy with chemotherapy can make treatment more effective in selected cases.

• Different side effect profile: Many patients experience fewer traditional chemotherapy-related effects, such as hair loss or nausea.

Limitations

• Subtype-specific use: Immunotherapy is currently effective for only a limited group of breast cancers.

• Response rates vary: Only around 20–30% of eligible patients respond significantly.

• Resistance can occur: Some tumors stop responding over time.

• Delayed benefit: Immunotherapy may take longer to show results than chemotherapy.

• Complex eligibility criteria: Biomarker testing is required, and not all clinics offer the same access.

Side Effects and Risks

Because immunotherapy activates the immune system, side effects can occur when the immune system also affects healthy tissues. Most side effects are manageable with monitoring and early treatment.

Common side effects

• Fatigue

• Skin rash or itching

• Mild digestive symptoms

• Infusion-related reactions (fever, chills, dizziness)

• Joint or muscle aches

Less common but serious side effects

• Colitis (bowel inflammation)

• Pneumonitis (lung inflammation)

• Hepatitis (liver inflammation)

• Endocrine disorders, including thyroid or adrenal dysfunction

• Long-term hormone changes, sometimes requiring ongoing medication

Patients are usually monitored closely, and immune-related side effects are treated with steroids or other immune-suppressing medications when needed.

Availability

Immunotherapy for breast cancer is available in many countries, but access varies depending on healthcare systems and approval status.

• Public hospitals: Many public cancer centres offer approved immunotherapy regimens for eligible patients.

• Private clinics: Private oncology clinics may offer access to immunotherapy, often with shorter waiting times.

• Specialised breast cancer centres: These centres typically provide the most up-to-date protocols and clinical trials.

• Cancer research hospitals: Academic centres may offer experimental immunotherapies through trials.

• Global variation: Availability is generally higher in North America, Europe, and parts of Asia, while access may be limited elsewhere.

Cost Overview

Immunotherapy is expensive, and costs vary widely by country, drug, and treatment duration.

• Annual costs can range from $100,000 to $150,000 USD without insurance or government coverage.

• In countries with universal healthcare, approved treatments are often subsidised.

• Private insurance may cover treatment but usually requires prior approval.

• Clinical trials may provide access at reduced or no cost to participants.

Patients should always confirm coverage, eligibility, and potential out-of-pocket expenses directly with healthcare providers.

How People Typically Find Clinics

Most people access breast cancer immunotherapy through established medical pathways rather than direct self-referral.

Common routes include:

• Oncologist referrals within hospital systems

• Multidisciplinary breast cancer teams, which coordinate care

• Cancer centres that specialise in advanced treatments

• Patient organisations and advocacy groups, which provide clinic listings

• Independent directories that allow users to browse immunotherapy clinics globally and compare services

Availability of specific treatments may differ between clinics, so direct confirmation is always important.

Closing Note

Immunotherapy has become an important treatment option for certain types of breast cancer, particularly triple-negative disease, and research continues to expand its role. While it offers meaningful benefits for some people, it is not suitable for everyone and requires careful evaluation. This article is intended to provide balanced, educational information to support further research and informed discussions with qualified healthcare professionals.

Disclaimer: This article is for informational purposes only and does not provide medical advice. Immunotherapy treatments, eligibility, and availability vary by country and individual circumstances. Always consult a qualified healthcare professional and verify information directly with medical providers.